Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with ...

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

There was a significant drop in the number of babies hospitalized with RSV this year; a positive news story that can be ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season.